RR

Rushikumarkanaiyalal Ribadiya

Active Director Director DIN 06919976
DIN 06919976 First appointment Oct 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Oct 2017
Shareholding value •••• Premium profile

About Rushikumarkanaiyalal Ribadiya

Data last updated:

Rushikumarkanaiyalal Ribadiya is a Director at Symbiosis Bioscience Private Limited (since 2023), Director at Axter Pharmaceuticals Private Limited (since 2020) and Designated Partner at Symbiosis Biolife Llp (since 2024), and holds 1 more current directorship. The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹7.55 Cr; the largest is Symbiosis Bioscience Private Limited at ₹4.13 Cr (FY 2025). Earlier, Rushikumarkanaiyalal Ribadiya was a Director at Laxter Pharmaceuticals Private Limited (2019–2021).

DIN 06919976
Primary Designation Director
Industry Pharma
First Appointment 20 Oct 2017
Oldest Company Age 12 yrs
Largest company Symbiosis Bioscience Private Limited · ₹4.13 Cr (FY 2025)
Combined revenue ₹7.55 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Symbiosis Bioscience Private Limited U24304GJ2022PTC134050
Director17 Oct 20232022₹4.13 Cr (FY 2025)Active
Director06 Mar 20202014₹3.43 Cr (FY 2025)Active
Designated Partner11 Mar 20242024Active
Lifekyor Overseas Private Limited U24111GJ2017PTC099549
Director20 Oct 20172017Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director09 May 20192018₹1.51 Cr (FY 2023)Under Process Of Striking Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Lifekyor Overseas Private Limited
Axter Pharmaceuticals Private Limited
Symbiosis Bioscience Private Limited
Symbiosis Biolife Llp
Premium access

Shareholding and investment profile for Rushikumarkanaiyalal Ribadiya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rushikumarkanaiyalal Ribadiya

Rushikumarkanaiyalal Ribadiya currently holds 4 directorships: Symbiosis Bioscience Private Limited (Director, since 17 Oct 2023, revenue ₹4.13 Cr (FY 2025)); Axter Pharmaceuticals Private Limited (Director, since 06 Mar 2020, revenue ₹3.43 Cr (FY 2025)); Symbiosis Biolife Llp (Designated Partner, since 11 Mar 2024); Lifekyor Overseas Private Limited (Director, since 20 Oct 2017).

Rushikumarkanaiyalal Ribadiya was first appointed on 20 Oct 2017 as Director at Lifekyor Overseas Private Limited. The most recent appointment on record is 11 Mar 2024 at Symbiosis Biolife Llp.

The 2 current companies of Rushikumarkanaiyalal Ribadiya that report revenue have a combined latest revenue of ₹7.55 Cr: Symbiosis Bioscience Private Limited ₹4.13 Cr (FY 2025); Axter Pharmaceuticals Private Limited ₹3.43 Cr (FY 2025).

Rushikumarkanaiyalal Ribadiya held 1 earlier board appointment: Laxter Pharmaceuticals Private Limited (Director, 09 May 2019 to 22 Jan 2021).

The current boards of Rushikumarkanaiyalal Ribadiya's companies include Jagdish Pravinbhai Hirani (Symbiosis Bioscience Private Limited), Kuldeep Kanaiyalal Ribadiya (Symbiosis Bioscience Private Limited), Sagar Pravinbhai Hirani (Symbiosis Bioscience Private Limited), Sakshi Laller (Symbiosis Bioscience Private Limited), Jagbir Singh (Lifekyor Overseas Private Limited), Manubhai Nagjibhai Jiyani (Lifekyor Overseas Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available